GNI Japan revises FY2023 profit forecast up ¥6.97B on conversion of Gyre preferred stock

GYRE THERAPEUTICS, INC.

GNI Japan recognized ¥8,873M other income from converting Gyre Series X Preferred into 8,767,333 common shares.
Revised FY2023 operating profit forecast ¥15,744M (up 116% from ¥7,280M); profit attributable to owners ¥8,971M (up 347%).
Revised EPS forecast ¥180.42 vs previous ¥42.20; prior year ¥8.19.
Conversion based on $0.51/share closing price of CBIO on Oct 30, 2023; shares to be issued Jan 22, 2024.
Forecast excludes mark-to-market of Gyre common stock; further discussions ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.